Pacritinib
4 clinical trials
2 abstracts
7 indications
Indication
T-cell neoplasmIndication
Lymphoproliferative DisordersIndication
Graft-Vs-Host DiseaseIndication
Graft-versus-host diseaseIndication
Graft-Versus-Host DiseaseAbstract
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.Org: Istituto di Ematologia s. Orsola-Malpighi,
Clinical trial
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)Status: Not yet recruiting, Estimated PCD: 2033-01-01
Clinical trial
Phase 2, Open Label, Multicenter Study of Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsStatus: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune SuppressionStatus: Completed, Estimated PCD: 2022-01-28
Clinical trial
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Status: Recruiting, Estimated PCD: 2024-11-02
Abstract
Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University Medical Center Hamburg-Eppendorf, Princess Margaret Cancer Centre, University Health Network, University College London Hospitals NHS Foundation Trust,